Artesunate + Mefloquine — Competitive Intelligence Brief

Artesunate + Mefloquine (Artesunate + Mefloquine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimalarial combination. Area: Infectious Disease.

marketed Antimalarial combination Plasmodium falciparum (multiple targets: artemisinin-induced reactive oxygen species; mefloquine-heme polymerase inhibition) Infectious Disease Small molecule

Target snapshot

Artesunate + Mefloquine (Artesunate + Mefloquine) — Armed Forces Research Institute of Medical Sciences, Thailand. Artesunate kills malaria parasites by generating reactive oxygen species that damage parasite proteins and membranes, while mefloquine inhibits parasite heme polymerization and disrupts mitochondrial function.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Artesunate + Mefloquine TARGET	Artesunate + Mefloquine	Armed Forces Research Institute of Medical Sciences, Thailand	marketed	Antimalarial combination	Plasmodium falciparum (multiple targets: artemisinin-induced reactive oxygen species; mefloquine-heme polymerase inhibition)
Sulfadoxine-pyrimethamine plus artesunate	Sulfadoxine-pyrimethamine plus artesunate	London School of Hygiene and Tropical Medicine	marketed	Antimalarial combination	Dihydrofolate reductase, dihydropteroate synthase (sulfadoxine-pyrimethamine); mitochondrial electron transport (artesunate)
artemether-lumefantrine (ALN)	artemether-lumefantrine (ALN)	Jhpiego	marketed	Antimalarial combination	Plasmodium falciparum heme metabolism and parasite membranes
AA(FDC)	AA(FDC)	Medecins Sans Frontieres, Netherlands	marketed	Antimalarial combination	Plasmodium falciparum (multiple mechanisms: artemisinin-based ROS generation and quinoline-based heme polymerization inhibition)
Mefloquine- Artesunate	Mefloquine- Artesunate	Centers for Disease Control and Prevention	marketed	Antimalarial combination	Parasite heme detoxification pathway; artemisinin-iron adducts generating reactive oxygen species
amodiaquine-artesunate versus amodiaquine	amodiaquine-artesunate versus amodiaquine	Charite University, Berlin, Germany	marketed	Antimalarial combination	Malaria parasite heme detoxification pathway; artemisinin-derived endoperoxide bridge
artesunate and mefloquine	artesunate and mefloquine	Mepha Ltd.	marketed	Antimalarial combination	Plasmodium falciparum heme iron (artesunate); parasite digestive vacuole and mitochondria (mefloquine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimalarial combination class)

1. Centers for Disease Control and Prevention · 4 drugs in this class
2. Armed Forces Research Institute of Medical Sciences, Thailand · 4 drugs in this class
3. London School of Hygiene and Tropical Medicine · 3 drugs in this class
4. Sanofi · 2 drugs in this class
5. Menzies School of Health Research · 2 drugs in this class
6. Fundação de Medicina Tropical Dr. Heitor Vieira Dourado · 1 drug in this class
7. Epicentre · 1 drug in this class
8. Jhpiego · 1 drug in this class
9. Charite University, Berlin, Germany · 1 drug in this class
10. Ifakara Health Institute · 1 drug in this class